原始来源记录
决策级顶线结果
Veradermics 报告 VDPHL01 在男性型脱发中的 2/3 期顶线数据呈阳性
302 研究 2/3 期达到了所有主要终点和关键次要终点，具有统计学意义。VDPHL01 在第 6 个月时，与安慰剂相比，非毳毛毛发数量和患者报告的毛发覆盖度均出现快速、剂量依赖性增加，安全性总体耐受性良好，无治疗相关 SAE 或心脏 AESI。
关键事实
来源摘录
mane-20260427 0001827635 False 0001827635 2026-04-27 2026-04-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2026 VERADERMICS, INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-43097 84-3304423 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 470 James Street New Haven , CT 06513 (Address of principal executive offices) (Zip Code) (Registrant’s telephone number, including area code): ( 228 ) 372-3376 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Fo